Edition:
India

People: Agios Pharmaceuticals Inc (AGIO.OQ)

AGIO.OQ on NASDAQ Stock Exchange Global Select Market

32.39USD
8:12pm IST
Change (% chg)

$-0.23 (-0.71%)
Prev Close
$32.62
Open
$32.50
Day's High
$32.50
Day's Low
$31.53
Volume
52,314
Avg. Vol
204,653
52-wk High
$74.12
52-wk Low
$31.04

Clancy, Paul 

Mr. Paul J. Clancy is Independent Director of Agios Pharmaceuticals, Inc. Mr. Clancy has served as a member of our board of directors since September 2013. Mr. Clancy has more than 20 years of experience in financial management and strategic business planning, and has served as chief financial officer of Alexion Pharmaceuticals, Inc., a public biopharmaceutical company, since July 2017. Prior to Alexion, Mr. Clancy served as the executive vice president and chief financial officer at Biogen Inc. (formerly known as Biogen Idec Pharmaceutical Corporation), or Biogen, since 2007. He also served as senior vice president of finance of Biogen Idec, with responsibilities for leading the treasury, tax, investor relations and business planning groups. Prior to the merger of Biogen and Idec Pharmaceutical Corporation, Mr. Clancy was the vice president of portfolio management at Biogen. He joined Biogen in 2001 as vice president of U.S. marketing. Before Biogen, Mr. Clancy spent 13 years at PepsiCo Inc., a publicly-traded food and beverage company, serving in a variety of financial and general management positions, including vice president and general manager of their Great West Business Unit. Mr. Clancy is a member of the board of directors and audit committee of Incyte Corporation, a biopharmaceutical company. Mr. Clancy has an M.B.A. from Columbia Business School and received his B.S. in business administration from Babson College in Wellesley, MA. We believe Mr. Clancy is qualified to serve as a member of our board of directors due to his extensive financial and executive leadership experience at large multi-national companies.

Basic Compensation

Total Annual Compensation, USD 70,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 484,141
Fiscal Year Total, USD 554,141

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --